These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 392366)

  • 21. Doxorubicin cardiomyopathy.
    Chatterjee K; Zhang J; Honbo N; Karliner JS
    Cardiology; 2010; 115(2):155-62. PubMed ID: 20016174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expectations and limitations of endomyocardial biopsy.
    Mills AS; Hastillo A; Thompson JA; Hess ML
    Can J Cardiol; 1985; 1(6):358-62. PubMed ID: 3915878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse.
    Bertazzoli C; Bellini O; Magrini U; Tosana MG
    Cancer Treat Rep; 1979; 63(11-12):1877-83. PubMed ID: 526920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Experimental morphological study, using electron microscopy, of adriamycin-induced cardiomyopathy].
    Accardo G; Aleotti A; Pazzi A; Tampieri ML; Zennaro A; Casaro S
    G Clin Med; 1983; 64(1-2):1-11. PubMed ID: 6862137
    [No Abstract]   [Full Text] [Related]  

  • 25. Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
    Mohamed HE; Asker ME; Ali SI; el-Fattah TM
    J Pharm Pharmacol; 2004 Jun; 56(6):757-68. PubMed ID: 15231041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calpain-mediated dystrophin disruption may be a potential structural culprit behind chronic doxorubicin-induced cardiomyopathy.
    Campos EC; O'Connell JL; Malvestio LM; Romano MM; Ramos SG; Celes MR; Prado CM; Simões MV; Rossi MA
    Eur J Pharmacol; 2011 Nov; 670(2-3):541-53. PubMed ID: 21946105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Experimental hepatopathy and myocardiopathy induced with adriamycin (histopathologic changes of the liver and myocardium caused by adriamycin in the rat)].
    Cuccurullo L; Vecchione R; Borrelli L; Battista O
    Pathologica; 1979; 71(1015):601-17. PubMed ID: 551385
    [No Abstract]   [Full Text] [Related]  

  • 28. [Cardiomyopathy due to adriamycin: the possibility of its prevention. Monitoring by noninvasive technics].
    Bianchi L; Bertocchi C; Felci U; Ferrario G; Giani P; Mariani L; Medolago G; Sarti E
    Minerva Med; 1989 Mar; 80(3):215-26. PubMed ID: 2717043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endocardial fibroelastosis associated with fatal adriamycin (doxorubicin) cardiomyopathy during treatment of Ewing's sarcoma.
    Conroy B; Guthrie W
    Scott Med J; 1983 Jul; 28(3):295-9. PubMed ID: 6612319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toxic cardiomyopathies.
    Balazs T; Herman EH
    Ann Clin Lab Sci; 1976; 6(6):467-76. PubMed ID: 793502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Fatal myocardiopathy due to adriamycin in spite of a reportedly non-dangerous cumulative dose].
    Battin J; Richir C; Bui NB; Hehunstre JP; Abecassis S
    Ann Pediatr (Paris); 1989 Feb; 36(2):136-40. PubMed ID: 2930128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cardiomyopathy after osteosarcoma treatment: a contribution to the cardiotoxicity of adriamycin].
    Geidel S; Garn M; Grävinghoff L; Hausdorf G; Morf G; Bielack S; Knop J; Winkler K
    Klin Padiatr; 1991; 203(4):257-61. PubMed ID: 1942931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heart rate dynamics in doxorubicin-induced cardiomyopathy.
    Lončar-Turukalo T; Vasić M; Tasić T; Mijatović G; Glumac S; Bajić D; Japunžić-Žigon N
    Physiol Meas; 2015 Apr; 36(4):727-39. PubMed ID: 25798626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recovery from anthracycline cardiomyopathy--how can it be explained?
    Christiansen S
    J Heart Lung Transplant; 2009 Jul; 28(7):751. PubMed ID: 19560709
    [No Abstract]   [Full Text] [Related]  

  • 35. The effect of EGb 761 on the doxorubicin cardiomyopathy.
    Timioğlu O; Kutsal S; Ozkur M; Uluoğlu O; Aricioğlu A; Cevik C; Düzgün E; Sancak B; Poyraz A
    Res Commun Mol Pathol Pharmacol; 1999; 106(3):181-92. PubMed ID: 11485048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adriamycin-induced myocardial toxicity: new solutions for an old problem?
    Outomuro D; Grana DR; Azzato F; Milei J
    Int J Cardiol; 2007 Apr; 117(1):6-15. PubMed ID: 16863672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Chronic toxicities of adriamycin (ADR) and their possible prevention by coenzyme Q10 and verapamil in rabbits--especially ADR induced cardiomyopathy (author's transl)].
    Dohmae N; Sawada H; Tashima M; Uchino H; Matsuyama E; Konishi T
    Nihon Gan Chiryo Gakkai Shi; 1979 Oct; 14(6):1009-28. PubMed ID: 541529
    [No Abstract]   [Full Text] [Related]  

  • 38. The meaning of bites on the vectorcardiogram: study in adriamycin cardiomyopathy.
    Vitolo E; Madoi S; Colli AM; Roveda M; La Rovere MT; Obbiassi M; Labianca R
    J Electrocardiol; 1982; 15(3):265-70. PubMed ID: 7119636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Cardiologic monitoring of patients under adriamycin therapy].
    Höfling B; Bolte HD
    Onkologie; 1981 Jun; 4(3):174-8. PubMed ID: 7022294
    [No Abstract]   [Full Text] [Related]  

  • 40. Cardiac magnetic resonance imaging for the assessment of the myocardium after doxorubicin-based chemotherapy.
    Lunning MA; Kutty S; Rome ET; Li L; Padiyath A; Loberiza F; Bociek RG; Bierman PJ; Vose JM; Armitage JO; Porter TR
    Am J Clin Oncol; 2015 Aug; 38(4):377-81. PubMed ID: 24192805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.